Approach to the patient with hidradenitis suppurativa: Evaluating severity to guide therapy - 01/12/24
Abstract |
Hidradenitis suppurativa (HS) is a chronic condition with a multifaceted pathoetiology requiring a multimodal management approach. The HS evaluation process involves the use of multiple tools to determine the extent and activity of disease, patient-reported outcomes, and the effectiveness of therapy. The multimodal approach to treatment based on severity includes lifestyle modifications, topical medications, systemic antibiotics, immunomodulators, and surgical interventions. Patients with HS benefit from medical optimization before surgical interventions. It is imperative to have treatment plans tailored to the disease severity and burden of each patient in order to effectively manage HS.
Le texte complet de cet article est disponible en PDF.Key words : acne inversa, hidradenitis suppurativa, therapy escalation
Abbreviations used : HS, PRO
Plan
Funding sources: None. |
|
Patient consent: Not applicable. |
|
Author Disclosures: Dr Shi is on the board of directors for the Hidradenitis Suppurativa Foundation, an advisor for the National Eczema Association, is a stock shareholder of Learn Health, and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Dermavant, Boehringer Ingelheim, Almirall, Alumis, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt's Bees, Galderma, Kiniksa, UCB, Ceraclere, Bain Capital, Target PharmaSolutions, Castle Bioscience, Altus Lab/cQuell, MYOR, Polyfins Technology, GpSkin, and Skin Actives Scientific. Dr Fragoso has served as a consultant for UCB and as an investigator for AbbVie, Amgen, Acelyrin, Takeda, and Target Derm. Author Dagenet and Dr Lee have no conflicts of interest to declare. |
|
Reviewer Disclosures: Steven Daveluy, MD, FAAD has disclosed the following relevant relationships – AbbVie (Speaker/Honoraria), Novartis (Speaker/Honoraria), Pfizer Inc. (Investigator/Grants & Research Funding), UCB (Consultant/Fees), UCB (Speaker/Honoraria), UCB (Investigator/Grants & Research Funding). |
|
IRB approval status: Not applicable. |
|
Date of release: December 2024. |
|
Expiration date: December 2027. |
Vol 91 - N° 6S
P. S22-S26 - décembre 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?